Turn Therapeutics (TTRX) Long-Term Deferred Tax (2025 - 2026)
Turn Therapeutics (TTRX) posted quarterly Long-Term Deferred Tax of $6.2 million for Q1 2026, up 4.01% quarter-over-quarter from $6.0 million in Q4 2025.
Turn Therapeutics (TTRX) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Turn Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $6.2 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (changed N/A YoY), while the FY2025 annual figure was $6.0 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $6.2 million, up from $6.0 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $6.2 million in Q1 2026, with the low at $6.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Turn Therapeutics | 285.07 Mn | 285.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.56 Mn |
| Mar 31, 2026 | 6.20 Mn |
| Dec 31, 2025 | 5.96 Mn |